| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/04/2002 | WO2002028347A3 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/04/2002 | WO2002012346A8 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 07/04/2002 | WO2002003991A3 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 07/04/2002 | WO2001091682A8 Composition and applicator for topical substance delivery |
| 07/04/2002 | WO2001090148A8 Neurotransmitter transporters |
| 07/04/2002 | WO2001089557A3 Methods for preventing strokes by inducing tolerance to e-selectin |
| 07/04/2002 | WO2001082916A3 Combination therapeutic compositions and methods of use |
| 07/04/2002 | WO2001078779A3 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001046176A3 Non peptide tachykinin receptor antagonists |
| 07/04/2002 | WO2001044260A9 Novel purines |
| 07/04/2002 | WO2001016096A3 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 07/04/2002 | US20020087015 High intestinal calcium transport activity and relatively high bone calcium mobilization activity; treating osteoporosis, cancer, psoriasis |
| 07/04/2002 | US20020086996 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates |
| 07/04/2002 | US20020086904 Methods of treating affective disorders using derivatives of (-)- venlafaxine |
| 07/04/2002 | US20020086891 Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols |
| 07/04/2002 | US20020086882 Regulates immune and inflammatory responses by binding to alpha 4 integrin, also know as Very Late Antigen; antiinflammatory agent |
| 07/04/2002 | US20020086871 Pharmaceutical composition for the treatment of CNS and other disorders |
| 07/04/2002 | US20020086865 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 07/04/2002 | US20020086864 Administering optically pure (S,S) enantiomer of reboxetine |
| 07/04/2002 | US20020086860 For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia |
| 07/04/2002 | US20020086859 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 07/04/2002 | US20020086858 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia |
| 07/04/2002 | US20020086832 Immunosuppressing a human after allogenic cell, tissue or organ transplantation by administering a caspase-8 inhibitor |
| 07/04/2002 | US20020086297 Gene alteration in the gene for the Gbeta3-subunit of the human G protein |
| 07/04/2002 | US20020086282 Methods and compositions for detecting compounds that modulate inflammatory responses |
| 07/04/2002 | US20020086067 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses |
| 07/04/2002 | US20020086049 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 07/04/2002 | US20020085615 Differential scanning calorimeter |
| 07/04/2002 | DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases |
| 07/04/2002 | DE10059144A1 Modulation der Transkription pro-inflammatorischer Genprodukte Modulating the transcription of pro-inflammatory gene products |
| 07/04/2002 | CA2626317A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2623600A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2623599A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2622727A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2622697A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2622477A1 Crystalline forms of atorvastatin |
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2433520A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | CA2433171A1 Human fgf23 protein mutants decreasing blood phosphorus level |
| 07/04/2002 | CA2433100A1 Indole derivatives as ligands of thyroid receptors |
| 07/04/2002 | CA2433090A1 Dipeptidyl peptidase iv inhibitor |
| 07/04/2002 | CA2432977A1 New use of artemin, a member of the gdnf ligand family |
| 07/04/2002 | CA2432570A1 New clinical treatment |
| 07/04/2002 | CA2432415A1 Acetyl-coenzyme a carboxylase 2 as a target in fat regulation and insulin action |
| 07/04/2002 | CA2432008A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 07/04/2002 | CA2431953A1 Piperidine mch antagonists and their use in the treatment of obesity |
| 07/04/2002 | CA2431883A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 07/04/2002 | CA2429773A1 Aerogel powder comprising therapeutic agents |
| 07/03/2002 | EP1219716A2 Diacylglycerol acyltransferase (DGAT) assay |
| 07/03/2002 | EP1219711A2 Lawsonia intracellularis vaccine |
| 07/03/2002 | EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) |
| 07/03/2002 | EP1219622A2 Pharmaceutical compositions for CNS and other disorders |
| 07/03/2002 | EP1219604A1 Method for improving the solubility of tricyclic amino alcohol derivatives |
| 07/03/2002 | EP1219599A1 Vitamin d derivatives having substituents at the 2 alpha-position |
| 07/03/2002 | EP1219595A1 O-anisamide derivatives |
| 07/03/2002 | EP1219297A1 Antiobestic agents |
| 07/03/2002 | EP1219292A1 Procedure or manufacturing dry powdered compositions comprising one or several oxygen-containing carotenoids |
| 07/03/2002 | EP1219182A2 Better tasting L-amino acid salts and their manufacture |
| 07/03/2002 | EP1218742A1 Spa in a screening method for modulators of glucokinase |
| 07/03/2002 | EP1218544A1 Methods for identifying rna binding compounds |
| 07/03/2002 | EP1218515A2 Regulation with binding cassette transporter protein abc1 |
| 07/03/2002 | EP1218509A2 Fibroblast growth factor-like polypeptides |
| 07/03/2002 | EP1218503A2 Fatty acid transport proteins |
| 07/03/2002 | EP1218498A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 07/03/2002 | EP1218491A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218401A1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 07/03/2002 | EP1218393A1 Cell targeting compositions and methods of using the same |
| 07/03/2002 | EP1218381A2 AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218379A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218378A2 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 07/03/2002 | EP1218373A2 2-pyrazolin-5-ones as tyrosine kinase inhibitors |
| 07/03/2002 | EP1218372A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1218361A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 07/03/2002 | EP1218358A1 Therapeutic quinazoline compounds |
| 07/03/2002 | EP1218348A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 07/03/2002 | EP1218346A1 Pyrazole derivatives |
| 07/03/2002 | EP1218342A2 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 07/03/2002 | EP1218341A1 Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| 07/03/2002 | EP1218333A1 Anti-inflammatory nitro- and thia- fatty acids |
| 07/03/2002 | EP1218021A1 Apple tree branch extracts for dermatological and cosmetic use and method for preparing same |
| 07/03/2002 | EP1218020A1 Treatment of diabetic nephropathy and microalbuminuria |
| 07/03/2002 | EP1218017A2 Combination of a statin and ex-vivo treated blood for treating atherosclerosis |
| 07/03/2002 | EP1218010A2 1,4-benzothiazepines to treat obesity related disorders |
| 07/03/2002 | EP1218008A2 New use of 1,2,4-triazolo[1,5-a]pyrimidines |
| 07/03/2002 | EP1218001A1 Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 07/03/2002 | EP1218000A1 Anti-cancer nitro- and thia-fatty acids |
| 07/03/2002 | EP1217996A1 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| 07/03/2002 | EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery |
| 07/03/2002 | EP1217902A1 Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions |
| 07/03/2002 | EP0983234B1 Leukotriene b 4 derivatives, in particular 7-methylcyclohexyl-ltb 4 antagonists |
| 07/03/2002 | EP0971729B1 Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| 07/03/2002 | EP0888112B1 New use of ammonium compounds and/or urea |
| 07/03/2002 | CN1357003A 类固醇衍生物 Steroid derivatives |
| 07/03/2002 | CN1356999A Polymroph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt |
| 07/03/2002 | CN1356986A Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical prepns. comprising them |
| 07/03/2002 | CN1356983A Tri-aryl acid derivatives as PPAR receptor ligands |
| 07/03/2002 | CN1356977A Glucagon antagonists/inverse agonists |